Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report ...

The report "Defense Platforms and Systems Outlook 2025: Emerging Technologies, Evolving Disruptions, Outlook and Growth Opportunities" ...

Tenpoint Therapeutics, Ltd. ("Tenpoint"), a global, clinical-stage biotechnology company focused on developing groundbreaking treatments to rejuvenate vision in the aging eye, today announced that the ...

Rein advanced the clinical development of its lead asset, LTI-03, and aims to initiate a Phase 2 trial for the treatment of idiopathic pulmonary f ...

Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for ...

Liquidia's collaboration with Sandoz and development of new products like L606 show promise. Learn why LQDA stock is a Hold.

The "Kidney Transplant Rejection - Market Insight, Epidemiology, and Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. The report delivers an in-depth understanding ...

ABL Bio Inc. (KOSDAQ: 298380), a clinical-stage biotech company developing bispecific antibody technology for immuno-oncology ...

NDA submission includes efficacy and safety data for the first fixed-dose combination therapy from the world's largest and longest study ever conducted in the presbyopia eye drop category Tenpoint ...

Ms. Whitaker is an accomplished C-suite leader, most recently as Chair and CEO of Aerami Therapeutics Holdings Inc. During her executive career she has held senior leadership roles at GlaxoSmithKline ...

(Reuters) -AbbVie on Thursday cut its 2025 adjusted profit forecast as the drugmaker expects to incur $248 million in acquisition-related expenses. The company expects adjusted profit in the range of ...

Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the ...